ValuEngine upgraded shares of Akari Therapeutics (NASDAQ:AKTX) from a strong sell rating to a sell rating in a research note issued to investors on Thursday morning.

Several other analysts have also recently issued reports on the stock. Zacks Investment Research upgraded shares of Akari Therapeutics from a sell rating to a hold rating and set a $5.00 target price on the stock in a research note on Monday, November 13th. Canaccord Genuity restated a buy rating and set a $15.00 price objective on shares of Akari Therapeutics in a research report on Friday, September 22nd. William Blair upgraded shares of Akari Therapeutics from a market perform rating to an outperform rating in a research report on Friday, September 22nd. Finally, Chardan Capital restated a neutral rating on shares of Akari Therapeutics in a research report on Sunday, September 17th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average price target of $7.50.

Akari Therapeutics (AKTX) traded down $0.02 during midday trading on Thursday, reaching $4.84. 102,461 shares of the company’s stock traded hands, compared to its average volume of 369,742. Akari Therapeutics has a fifty-two week low of $3.18 and a fifty-two week high of $22.20.

An institutional investor recently bought a new position in Akari Therapeutics stock. Hikari Power Ltd acquired a new stake in shares of Akari Therapeutics PLC (NASDAQ:AKTX) during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 60,012 shares of the biopharmaceutical company’s stock, valued at approximately $277,000. Hikari Power Ltd owned approximately 0.51% of Akari Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 21.06% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was illegally stolen and republished in violation of US and international copyright and trademark legislation. The original version of this story can be read at

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal hemoglobinuria, Guillain Barre syndrome and atypical Hemolytic Uremic Syndrome.

Receive News & Stock Ratings for Akari Therapeutics PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics PLC and related stocks with our FREE daily email newsletter.